Combined analysis of mRNA expression of ERCC1,BAG-1,BRCA1,RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy

Background: the aim of this study was to investigate prognostic value of excision repair cross-complementing 1 (ercc1),bcl2-associated athanogene (bag-1),the breast and ovarian cancer susceptibility gene 1 (brca1),ribonucleotide reductase subunit m1 (rrm1) and class iii -tubulin (tubb3) in patients with non-small cell lung cancer (nsclc) who received platinum- based adjuvant chemotherapy. methods. messenger rna expressions of these genes were examined in 85 tumor tissues and 34 adjacent tissue samples using semi-quantitative rt-pcr. the expressions of these five genes were analyzed in relation to chemotherapy and progression-free survival (pfs) and overall survival (os). seventy-four patients were enrolled into chemotherapy. results: patients with ercc1 or bag-1 negative expression had a significantly longer pfs (p = 0.001 and p = 0.001) and os (p = 0.001 and p = 0.001) than those with positive expression. patients with negative ercc1 and bag-1 expression benefited more from platinum regimen (p = 0.001 and p = 0.002). patients with brca1 negative expression might have a longer os (p = 0.052),but not pfs (p = 0.088) than those with brca1 positive expression. a significant relationship was observed between the mrna expression of ercc1 and bag-1 (p = 0.042). in multivariate analysis,ercc1 and bag-1 were significantly favorable factors for pfs (p = 0.018 and p = 0.017) and os (p = 0.027 and p = 0.022). conclusions: ercc1 and bag-1 are determinants of survival after surgical treatment of nsclc,and its mrna expression in tumor tissues could be used to predict the prognosis of nsclc treated by platinum. © 2012 leng et al; licensee biomed central ltd.